What happens to the heart and blood vessels after COVID‑19?

The cardiovascular burden of COVID‑19

Although COVID‑19 was initially seen primarily as a respiratory disease, it has become clear that the virus can significantly affect the cardiovascular system—both acutely and in the longer term (“long COVID”). For example:

In a large meta‑analysis of nearly three million people, chest pain was reported in ~22% of post‑COVID patients, palpitations ~18%, hypertension ~19%.
In imaging studies, people with prior SARS‑CoV‑2 infection had faster progression of coronary atherosclerotic plaque, especially non‑calcified, high‑risk types—suggesting the infection accelerates vascular ageing.
Vascular review papers describe persistent endothelial dysfunction (endotheliopathy), hypercoagulable states, microvascular injury, and vascular inflammation long after the acute infection.
Regarding the heart, acute cardiac injury (myocardial injury, myocarditis, arrhythmias) during acute COVID‑19 is well documented. Follow‑up studies indicate elevated risk for new heart failure, arrhythmias and cardiovascular events.

Mechanisms of cardiovascular damage

How does SARS‑CoV‑2 produce this damage? The mechanisms are multi‑factorial:

Endothelial/perivascular injury: SARS‑CoV‑2 can infect vascular smooth muscle or pericytes, and via inflammatory signals trigger endothelial dysfunction indirectly. For example, a stem‑cell derived vascular cell model showed smooth muscle cells became infected and signalled to endothelial cells, causing barrier weakening, reactive oxygen species, coagulation gene expression.
Inflammation/coagulation cascade: The “cytokine storm” and high levels of inflammatory mediators in COVID can damage vascular endothelium, promote thrombosis, microvascular leakage and contribute to fibrosis.
Direct myocardial injury / remodeling: Cardiomyocytes may be infected or stressed; inflammation, microvascular damage, hypoxia, and myocarditis all play a role. Cardiomyocyte models derived from pluripotent stem cells (PSCs) show structural and functional changes after SARS‑CoV‑2 exposure.
Long‑term sequelae: Persistent endothelial dysfunction may lead to vascular stiffening, microvascular rarefaction, impaired vasodilation, and over time accelerate atherosclerosis and increased cardiovascular risk.

Clinical relevance

For patients who have had COVID‑19, particularly moderate to severe disease, the result may be:

Persistent cardiovascular symptoms (palpitations, chest discomfort, dyspnoea)
New or worsening heart failure (especially in those who already had cardiovascular disease)
Accelerated vascular disease (plaque progression, increased risk of MI/stroke)
Microvascular and macrovascular dysfunction (impaired vasodilation, vessel stiffness)

In other words: in survivors of COVID‑19 there is a real cardiovascular burden—and for patients experiencing long COVID symptoms involving the heart or circulation, this is clinically relevant.

What is the rationale for stem‑cell / regenerative therapy in cardiovascular damage?

Given the above cardiovascular insults, the question is: can regenerative medicine (such as the stem cell therapies offered at Dekabi Stem Cell Clinic) help reverse or mitigate this damage? Let’s map the rationale.

What can stem cells/regenerative therapies do?

“Stem cell therapy” is a broad term but in the cardiovascular context, common aims include:

Promote angiogenesis (new blood vessel formation) in damaged areas, thereby improving perfusion
Modulate inflammation and reduce fibrosis (scar tissue) in myocardium or damaged vessels
Potentially replace or support damaged cardiomyocytes or vascular cells (endothelial, smooth muscle)
Improve microvascular structure, reduce vascular stiffness, improve endothelial function
Provide paracrine factors (growth factors, exosomes) that stimulate endogenous repair

Meta‑analyses and systematic reviews show promise: for example, MSC (mesenchymal stem cell) therapy in heart failure (reduced ejection fraction) demonstrated improvements in quality of life though modest effect on ejection fraction. Pluripotent stem cell approaches for cardiac repair are also being developed (though primarily still preclinical) with focus on improving engraftment, vascularisation, safety.

How this maps to post‑COVID cardiovascular damage?

Here’s how the mechanisms of stem cell/regenerative therapy could theoretically help in the post‑COVID scenario:

If COVID caused endothelial damage, microvascular rarefaction or vascular stiffening → regenerative therapy could target vascular repair: improving endothelial function, promoting micro‑vessel growth, reducing fibrosis in vascular walls.
If COVID caused myocardial injury/ fibrosis (from myocarditis, hypoxia, microvascular injury) → stem cells could help by modulating scar tissue, promoting microvascularisation, even supporting cardiomyocyte function (directly or via paracrine signalling).
If systemic inflammation (persistent) is driving vascular ageing/atherosclerosis post‑COVID → the immunomodulatory effects of MSCs might reduce ongoing damage.
The clinic’s specialised focus on regenerative and anti‑aging medicine could create a holistic framework: supporting circulation, metabolic health, inflammation, complementing stem‐cell therapy.

Important nuances

However, there are important caveats:

Stem cell therapies are not magic bullets: they do not yet reliably “replace” large volumes of damaged cardiomyocytes in clinical practice.
The type of damage matters: diffuse microvascular impairment or endothelial dysfunction may respond differently than large scar tissue from infarction.
Timing, delivery route, cell type, dose, patient selection all influence efficacy. Many variables remain under investigation.
Post‑COVID cardiovascular damage is relatively new—there are no large large‑scale trials yet specifically for stem cell therapy in this context. So much is theoretical/extrapolated from other cardiovascular conditions.

What does the current evidence show for stem cell/regenerative therapy in cardiovascular disease and by extension, post‑COVID cardiovascular damage?

Evidence in cardiovascular disease (non‑COVID)

Since the post‑COVID scenario is newer, the best we can do is review the cardiovascular regenerative therapy evidence broadly.

A systematic review/meta‑analysis regarding MSC therapy in heart failure (HFrEF) showed a small, non‑significant improvement in left ventricular ejection fraction (LVEF) but significant improvement in quality of life; and was safe (no increase in major adverse cardiac events).
A review on stem cell therapy in ischemic heart disease concluded that while promising, translation to routine practice is still limited—especially for acute myocardial infarction.
Challenges identified include: low retention/survival of transplanted cells, limited engraftment, difficulty in delivering cells effectively to damaged tissue, identifying optimal cell type and dose.
Advances are ongoing: e.g., MSC‑derived exosomes (cell‑free therapy) are emerging for cardiac regeneration, which may overcome some of the challenges of cell transplantation.

Evidence in COVID / post‑COVID regenerative therapy

Specifically in the COVID/post‑COVID realm:

There is evidence of stem cell therapy being used for severe acute COVID‑19 (mainly lung/respiratory therapy): A 3‑year follow‑up of a randomized, double‑blind, placebo‑controlled trial of umbilical‑cord MSCs in severe COVID‑19 found safety over 3 years and some benefit in lung imaging and quality of life—but this was not cardiovascular‑specific.
Regarding cardiovascular modelling: In vitro studies using human pluripotent stem cell‑derived cardiomyocytes (hPSC‑CMs) have shown how SARS‑CoV‑2 can alter cardiomyocyte structure/function, and these studies can help identify therapeutic targets.
But as of now, there is very limited clinical trial data on stem cell therapies specifically for heart or vascular damage post‑COVID. Most of the evidence is mechanistic, preclinical or extrapolated from other cardiovascular disease settings.

Summary of evidence: pros and cons

Pros:

Stem cell therapy has a sound mechanistic rationale for cardiovascular repair (angiogenesis, anti‑inflammation, paracrine support, microvascular repair).
Safety in many cardiovascular stem cell trials has been reasonably good.
For post‑COVID patients with cardiovascular symptoms and documented vascular/myocardial injury, regenerative therapy offers a novel option beyond standard medical management.

Cons / Limitations:

No large randomized controlled trials yet in post‑COVID cardiovascular damage.
Many uncertainties: which patients will benefit most, what stem cell source/route/dose is optimal, when to treat (early vs late), how to monitor effect.
Retention/engraftment of stem cells remains low; effects sometimes modest.
Costs, regulatory issues, and ensuring robust long‑term outcomes remain real challenges.

Applying this to post‑COVID heart and vascular damage: can stem cells help reverse it?

Putting this all together: for a patient who has had COVID‑19 and is now experiencing heart or vascular damage (e.g., endothelial dysfunction, microvascular impairment, myocardial scarring, increased plaque vulnerability)—how might regenerative or stem cell therapy help, and what realistically can be expected?

What “reversal” means in this context?

Firstly, “reversal” doesn’t necessarily mean full restoration of completely normal heart/vascular anatomy. More realistically, beneficial outcomes might include:

Improved vascular/endothelial function (better vasodilation, less stiffness)
Improved microvascular perfusion (better circulation in heart/other organs)
Reduced ongoing vascular inflammation, slowed progression of vascular disease
Improved myocardial function (better contractility, less remodeling, fewer symptoms)
Improved symptoms (less chest discomfort, palpitations, fatigue) and improved quality of life

How stem cell therapy at a clinic could be applied?

At a specialised regenerative medicine clinic such as the Dekabi Stem Cell Clinic, with expertise in stem cell therapy, chronic disease management and anti‑aging medicine, the following approach could make sense:

Patient selection and evaluation: Identify patients with documented post‑COVID cardiovascular damage (e.g., via imaging — cardiac MRI, coronary CT, endothelial function tests, etc).
Personalised treatment plan: Given the clinic’s philosophy of “1:1 personalised stem cell therapy”, the regimen could tailor stem cell source (e.g., mesenchymal stem cells), delivery method (intravenous, intracoronary, intramyocardial, depending on risk/benefit), adjunct therapies (detox, energy medicine, anti‑inflammation, metabolic optimisation).
Adjunct holistic care: Since cardiovascular repair is affected by systemic factors (metabolism, inflammation, vascular risk factors), the clinic’s holistic/regenerative approach (anti‑aging, chronic disease management) is well aligned.
Monitoring and follow‑up: Given the emerging nature of evidence, close monitoring of vascular function (endothelial testing), myocardial function (echo, MRI), biomarkers of inflammation/coagulation, as well as patient‑reported outcomes (symptoms, quality of life) will be important.

Expectations and realistic outcomes

It’s important for patients and clinicians to set realistic expectations:

While stem cell/regenerative therapy could improve function and symptoms, complete reversal of extensive damage (significant myocardial scar, advanced vascular plaque) may not yet be reliably achieved.
Effectiveness likely better when the damage is not too advanced (less extensive scarring/fibrosis), and when therapy is applied early enough rather than many years later.
Therapy is adjunct to standard cardiovascular care, not a substitute for good vascular risk factor control (blood pressure, lipids, diabetes, lifestyle).
Because post‑COVID cardiovascular damage is relatively new, outcomes data are still evolving; hence patients should understand the experimental/innovative nature of regenerative therapy in this context.

Specific mechanisms relevant to post‑COVID damage

For endothelial dysfunction post‑COVID: MSCs or endothelial progenitor cell approaches could improve endothelial repair, reduce stiffness or microvascular impairment.
For microvascular injury (in heart or other organs): regenerative therapy might promote angiogenesis, restore micro‑circulation.
For myocardial injury / post‑myocarditis: even if cardiomyocyte loss occurred, stem cell therapy may reduce ongoing remodeling, promote supportive vasculature, and improve function (though replacing large numbers of cardiomyocytes remains challenging).
For accelerated atherosclerosis / plaque progression: while stem cell therapy is less studied in this domain, by reducing vascular inflammation and improving endothelial health, there is theoretical benefit.

How to move forward: Practical considerations & recommendations

Pre‑treatment evaluation

Before considering regenerative therapy for post‑COVID cardiovascular damage, patients should undergo:

Comprehensive cardiovascular assessment: imaging (echocardiogram, cardiac MRI if available), coronary CT/angiography if indicated; endothelial/vascular function tests (flow‑mediated dilation, stiffness).
Detailed history including severity of COVID‑19 infection, pre‑existing cardiovascular risk factors (hypertension, diabetes, hyperlipidaemia).
Biomarker evaluation: markers of inflammation, coagulation, endothelial injury.
Standard care optimisation: ensure blood pressure, lipids, glucose, lifestyle factors (diet, exercise, smoking) are addressed.

Treatment protocol considerations

At a regenerative clinic the following are key:

Stem cell source: Mesenchymal stem cells (MSCs) are the most widely used in cardiovascular trials. Others include induced pluripotent stem cell (iPSC) derived cardiomyocytes, endothelial progenitor cells—though their use is more experimental.
Delivery route and timing: For vascular/endothelial repair, intravenous or intra‑arterial routes may suffice; for myocardial repair, intracoronary or intramyocardial injections may be needed (with higher risk). Timing is important: earlier may yield better outcomes.
Adjunct therapies: Anti‑inflammatory support, metabolic optimisation (insulin resistance, dyslipidaemia), anti‑oxidant/anti‑aging support, vascular lifestyle interventions.
Personalised dose and regimen: The clinic’s philosophy of 1:1 therapy is appropriate, but standardisation is challenging—both clinician and patient should understand that protocol variation remains.
Safety monitoring: While many trials show good safety of MSC therapy, any stem cell therapy (especially novel cell types) requires monitoring for arrhythmia risk, immunologic issues, tumour risk (though low with MSCs), and graft/host responses.

Follow‑up and outcome assessment

Regular imaging/functional tests to assess improvement (e.g., improvement in endothelial function, myocardial strain, scar size, vascular stiffness).
Symptom and quality‑of‑life assessment.
Long‑term follow‑up: cardiovascular outcomes, event rates (MI, heart failure hospitalisation) should ideally be tracked.
Be realistic about incremental improvements rather than dramatic reversal.

Given the emerging evidence:

Inform patients that while regenerative therapy is promising, it is still not standard of care for post‑COVID cardiovascular damage.
Discuss risks, costs, and the fact that benefit may be moderate and not guaranteed.
Emphasise that stem cell therapy is complementary to standard cardiovascular care, not a replacement.
Make clear the need for ongoing follow‑up, possibly in research/trial contexts.

Conclusion

In summary:

COVID‑19 can cause significant and sometimes long‑lasting damage to the heart and blood vessels—via endothelial injury, microvascular damage, myocardial injury, inflammation and vascular acceleration of disease.
Regenerative medicine, including stem cell therapy, offers a compelling scientific rationale for addressing these types of damage—through vascular repair, angiogenesis, anti‑inflammation, support of myocardial tissue.
While there is promising evidence in cardiovascular disease generally, direct evidence specific to post‑COVID heart and vessel damage is still limited.
For patients with post‑COVID cardiovascular issues, a well‑resourced specialised regenerative clinic (like Dekabi Stem Cell Clinic) may offer a thoughtful, personalised approach—particularly where conventional therapies are optimised and the patient is well selected.
However: patients must be counselled carefully, expectations managed, and therapy viewed as part of a broader cardiovascular and regenerative care strategy—not a guarantee of full reversal.

From the standpoint of a clinic with 22 years of stem cell therapy experience and over 34 years in medicine, this is an exciting domain to engage in, but also one that requires scientific rigour, patient‑education, and transparent communication about what is known and what remains investigational.